Skip to content
Screener

Kymera Therapeutics KYMR Q2 2025 earnings

Reported August 11, 2025 · Before market open

Revenue$11.5MMiss by $5.7M
EPS-$0.95Miss by $0.12
Revenue estimate$17.1M
EPS estimate-$0.83

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$1.25

Financials

Q2 2025

Income statement

See full
Revenue$11.5M-55.3%
Operating income-$84.6M-66.0%
Net income-$76.6M-82.1%
EPS (diluted)-$0.95-63.8%

Balance sheet

See full
Cash & equivalents$335.8M+397%
Total debt$87.6M-1.7%
Total equity$971.5M+41.8%
Total assets$1.1B+36.9%

Cash flow

See full
Operating cash flow-$59.9M-39.5%
CapEx$695.0K-85.2%
Free cash flow-$60.6M-27.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$3.07B+40.8%
Enterprise value$2.82B+28.1%
P/S68.7×+44.0×

Profitability

See full
Operating margin-697.5%-1,223pp
Net margin-616%-1,039pp
FCF margin-565.7%-912pp

Returns & leverage

See full
Return on equity-33.3%+7.3pp
Debt / equity0.1×0.0×
Current ratio8.3×-0.1×

FAQ

When did Kymera Therapeutics report Q2 2025 earnings?
Kymera Therapeutics (KYMR) reported Q2 2025 earnings on August 11, 2025 before market open.
What were Kymera Therapeutics's Q2 2025 revenue and EPS?
Kymera Therapeutics reported revenue of $11.5M and eps of $-0.95 for Q2 2025.
Did Kymera Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $17.1M by $5.7M. EPS missed the consensus estimate of $-0.83 by $0.12.
How did Kymera Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 55.3% from $25.7M a year earlier and eps declined 63.8% from $-0.58.
Where can I find Kymera Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-106227) and the 10-Q periodic report (0000950170-25-106229) directly on SEC EDGAR. The filing index links above go to sec.gov.